The Trend of Targeted Therapies in Chinese Patients With Ankylosing Spondylitis: Results From a Real-Life Survey

被引：1

作者：

Wen, Yiquan ^{[1
]}

Hu, Zhuoran ^{[2
]}

Xie, Baozhao ^{[3
]}

Yuan, Fei ^{[4
]}

Xie, Zhengquan ^{[5
]}

Jiang, Yutong ^{[2
]}

Lin, He ^{[6
]}

Qi, Jun ^{[2
]}

Chen, Qiyun ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 3, Div Rheumatol, Yuedong Hosp, Meizhou, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 3, Div Rheumatol, Guangzhou, Peoples R China

[3] Wuzhou GongRen Hosp, Div Rheumatol, Wuzhou, Peoples R China

[4] Dongguan Peoples Hosp, Div Rheumatol, Dongguan, Peoples R China

[5] Panyu Hosp Chinese Med, Div Rheumatol, Guangzhou, Peoples R China

[6] Fujian Prov Hosp, Div Rheumatol, Fuzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2021年 / 12卷

关键词：

ankylosing spondylitis; biologics; preference; Chinese; cross-sectional study; RECOMMENDATIONS;

D O I：

10.3389/fphar.2021.763707

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Targeted medication, including mostly biologics and small-molecule chemical drugs, is an important therapy for ankylosing spondylitis (AS). There are still limited data on the preference of different targeted drugs in Chinese AS patients. Methods: A questionnaire-based cross-sectional study was performed on AS patients from six hospitals in three provinces in South China. Anti-rheumatic diseases' medication history includes the recent and previous usage of biologics or Janus kinase inhibitors (JAKi) in the last complete course of treatment, disease severity, and reasons for targeted-treatment change or preference. Results: 354 of 366 participants responded to the online survey. The participants' median age was 32 years, with a median of 7.3 years of disease duration; 79.7% were male. 63.6% of them were in the course of biologics or JAKi. Generic ETN is the most widely used and willing-to-use biologic though the proportion of its usage shrunk in the present compared with the past. The choice of original-branded ADA demonstrated an increase in usage. The preference of secukinumab and tofacitinib depicted a quick ascending trend. Conclusion: TNF-alpha inhibitors (TNFi) are still the most popular targeted medication for AS in China. Their price influences patients' preferences mostly. The doctor's recommendation is also part of the equation. Rheumatologists should pay more attention to patients' education to formulate targeted therapeutic plans.

引用

页数：5

共 15 条

[1] Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial [J].

Baraliakos, Xenofon ;

Gossec, Laure ;

Pournara, Effie ;

Jeka, Slawomir ;

Mera-Varela, Antonio ;

D'Angelo, Salvatore ;

Schulz, Barbara ;

Rissler, Michael ;

Nagar, Kriti ;

Perella, Chiara ;

Coates, Laura C. .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) :582-590

[2] Secukinumab: A Review in Ankylosing Spondylitis [J].

Blair, Hannah A. .

DRUGS, 2019, 79 (04) :433-443

[3] 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis [J].

Braun, J. ;

van den Berg, R. ;

Baraliakos, X. ;

Boehm, H. ;

Burgos-Vargas, R. ;

Collantes-Estevez, E. ;

Dagfinrud, H. ;

Dijkmans, B. ;

Dougados, M. ;

Emery, P. ;

Geher, P. ;

Hammoudeh, M. ;

Inman, R. D. ;

Jongkees, M. ;

Khan, M. A. ;

Kiltz, U. ;

Kvien, T. K. ;

Leirisalo-Repo, M. ;

Maksymowych, W. P. ;

Olivieri, I. ;

Pavelka, K. ;

Sieper, J. ;

Stanislawska-Biernat, E. ;

Wendling, D. ;

Ozgocmen, S. ;

van Drogen, C. ;

van Royen, B. J. ;

van der Heijde, D. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :896-904

[4] Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease [J].

Burmester, Gerd R. ;

Panaccione, Remo ;

Gordon, Kenneth B. ;

McIlraith, Melissa J. ;

Lacerda, Ana P. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (04) :517-524

[5] Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data [J].

Deodhar, A. ;

Mease, P. J. ;

McInnes, I. B. ;

Baraliakos, X. ;

Reich, K. ;

Blauvelt, A. ;

Leonardi, C. ;

Porter, B. ;

Gupta, A. Das ;

Widmer, A. ;

Pricop, L. ;

Fox, T. .

ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)

[6]

GARRETT S, 1994, J RHEUMATOL, V21, P2286

[7] Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries [J].

Glintborg, B. ;

Lindstrom, U. ;

Aaltonen, K. ;

Kristianslund, E. K. ;

Gudbjornsson, B. ;

Chatzidionysiou, K. ;

Askling, J. ;

Nordstrom, D. ;

Hetland, M. L. ;

Di Giuseppe, D. ;

Dreyer, L. ;

Kristensen, L. E. ;

Jorgensen, T. S. ;

Eklund, K. ;

Grondal, G. ;

Ernestam, S. ;

Joensuu, J. ;

Tormanen, M. R. K. ;

Skydsgaard, H. ;

Hagfors, J. ;

Kvien, T. K. ;

Lie, E. ;

Fagerli, K. ;

Geirsson, A. J. ;

Jonsson, H. ;

Provan, S. A. ;

Krogh, N. S. ;

Jacobsson, L. T. H. .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 (06) :465-474

[8] Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality A Population-Based Study [J].

Haroon, Nisha Nigil ;

Paterson, J. Michael ;

Li, Ping ;

Inman, Robert D. ;

Haroon, Nigil .

ANNALS OF INTERNAL MEDICINE, 2015, 163 (06) :409-+

[9] Make up a missed lesson-New policy to ensure the interchangeability of generic drugs in China [J].

Huang, Baobin ;

Barber, Sarah L. ;

Xu, Mingzhe ;

Cheng, Shuanghong .

PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (03)

[10] Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease [J].

Masters, Seth L. ;

Simon, Anna ;

Aksentijevich, Ivona ;

Kastner, Daniel L. .

ANNUAL REVIEW OF IMMUNOLOGY, 2009, 27 :621-668

← 1 2 →